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An eﬃcient and highly selective multicomponent synthesis of 4-aminoimidazo[1,2-a][1,3,5]triazines, which
are 5-aza-7-deaza-isosteres of adenine, was developed. The reaction of 2-aminoimidazoles, triethyl
orthoformate and cyanamide under microwave irradiation proceeded regioselectively to provide a library
of novel 5-aza-7-deaza-adenines in good yields and purity. The developed method was demonstrated
to be scalable and highly reproducible in three diﬀerent monomode microwave reactors. A
rearrangement was proposed to explain the high selectivity of the reaction.Introduction
Purine is a heterocyclic scaﬀold of primary importance in
nature. Purine bases adenine and guanine encode half of the
genetic information in DNA molecules.2 Being the most ubiq-
uitous nitrogen-containing heterocycle in nature, purine serves
as a scaﬀold for molecules involved in the functioning of
thousands of proteins in the human body.3 Thus, purines have
become a privileged scaﬀold in drug discovery and develop-
ment, inspiring also research in the area of structurally related
heterocyclic systems i.e. purine isosteres. Among 1,3,5-triazine
based purine isosteres, 5-azapurines (1,2,4-triazolo[1,5-a][1,3,5]
triazines)4 and 5-aza-9-deazapurines (pyrazolo[1,5-a][1,3,5]
triazines)5 have been widely investigated and considerable
success has been achieved in the development of new bioactive
compounds based on these scaﬀolds.6 Due to limited methods
for their preparation, biological activity of imidazo-fused 1,3,5-
triazines has been less explored. However, the 5-aza-7-deaza-
isostere of the purine system (imidazo[1,2-a][1,3,5]triazine)
has been employed as a scaﬀold for the construction of inhib-
itors of therapeutically valuable enzymes: activated Cdc42-alaysia, Jalan Lagoon Selatan, Bandar
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8associated tyrosine kinase 1,7 focal adhesion kinase,8 and
dipeptidyl peptidase IV.9 Some 5-aza-7-deazapurines were
claimed to be agonists of opioid m-receptors,10 ligands of
adenosine receptors,11 and potential antiviral agents.12
The search for bioactive molecules among aza-/deaza-
isosteres of adenine has been an eﬃcient research strategy in
medicinal chemistry. For example, the 8-aza-7-deaza-adenine
analogue 1 (Chart 1) was developed as an isosteric modica-
tion of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), the
earliest selective inhibitor of phosphodiesterase 2 (PDE2).13
Compound 1 was found to be much more potent inhibitor of
PDE2, inhibiting this enzyme with Ki value of 0.053 nM
(compared with Ki ¼ 7 nM for EHNA).14 Another 8-aza-7-deaza-
adenine based drug ibrutinib (2) has been recently approved forChart 1 Biologically active aza-/deaza-isosteres of adenine.
This journal is © The Royal Society of Chemistry 2017
Paper RSC Advancesthe treatment of mantle cell lymphoma and chronic lympho-
cytic leukemia.15 7-Deaza-adenine derivative CGP62464 (3)
was found to be a potent inhibitor of Src family kinases.16 An
antiviral agent inhibiting S-adenosyl homocysteinase
was developed on the 5-aza-9-deaza-adenine scaﬀold
(compound 4).17
The discovery of bioactive aza/deaza isosteres of adenine has
encouraged us to develop new and eﬀective methods for the
synthesis of compounds within this general framework. As part
of our ongoing research program on practical approaches for
preparation of 1,3,5-triazine based purine-like compounds, in
this contribution we report a new method for the synthesis of
4-aminoimidazo[1,2-a][1,3,5]triazines (6), which are 5-aza-7-
deaza-isosteres of adenine.
The annulation of imidazole onto the 1,3,5-triazine ring
was the rst and has been the most common approach re-
ported to date for the synthesis of imidazo[1,2-a][1,3,5]
triazines.18–20 We decided to investigate the less explored
annulation of the 1,3,5-triazine ring onto substituted 2-ami-
noimidazoles. Our group has previously achieved successful
annulation of 1,3,5-triazine ring onto aminoazoles viz. 5-ami-
nopyrazoles and 5-aminotriazoles via their three-component,
microwave-assisted reaction with orthoformates and cyana-
mide.21 Herein we extend this methodology to a similar
heterocyclic system preparing hitherto unknown 5-aza-7-
deaza-adenines via our multicomponent, microwave-assisted
reaction using 2-aminoimidazoles. These substrates are
diﬀerent from those previously used by their signicantly
greater basicity. Moreover, regioselectivity of the ring closure
could be a potential challenge for non-symmetrically
substituted 2-aminoimidazoles due to the similarity of their
reactive endocyclic nitrogen atoms.
Results and discussion
Synthesis
The optimisation of conditions for the multicomponent reaction
was performed with 2-amino-4-phenylimidazole (5a) as a model
substrate (1 mmol in 2 mL of solvent) using the Discover SP
(CEM) microwave synthesizer (Table 1). Initially, we attempted
a one-pot, three-component reaction of 5a with triethyl ortho-
formate and cyanamide inmethanol undermicrowave irradiation
at 150 C for 25 min (Entry 1). To our satisfaction, the product 6a
was obtained in high purity aer simple ltration, but the yield
was rather low (26%). The analysis of the ltrate revealed the
presence of a substantial quantity of unreacted 5a together with
the product. In the screening of solvents for this reaction, we
found that the yield of isolated product could be improved to 61%
when the reaction was carried out in ethyl acetate (Entry 6).
Continuing optimisation of the reaction conditions by altering
the time of reaction, we found that shortening the reaction time
to 20min gave further improvement in the yield (Entry 7). Varying
reagent ratio revealed that 6a could be obtained in a better yield
using the 1 : 2.5 : 2.5 ratio of 5a, triethyl orthoformate and cyan-
amide, respectively (Entry 10). The further increase of this ratio to
1 : 3 : 3 as well as changes of the reaction temperature did not
improve the outcome of reaction. It should be noted that increaseThis journal is © The Royal Society of Chemistry 2017of the reaction temperature to 160 C resulted in the substantial
loss of the product purity. For comparison purposes, we also
performed the reaction using conventional heating under reux
in ethyl acetate. The reux of the reagents in the optimised ratio
for 24 h enabled us to isolate the desired product 6a in 13% yield.
The developed method was validated using three diﬀerent
models of microwave synthesizers: Discover SP (CEM), Mono-
wave 450 (Anton Paar), and Initiator+ (Biotage). The three-
component reaction of 5a, triethyl orthoformate and cyana-
mide under optimised conditions was conducted with all three
systems in triplicates. Similar results were obtained for all three
reactors: 83%, 80%, and 75% for Discover SP, Monowave 450,
and Initiator+, respectively. We also attempted to scale up our
microwave-assisted reaction by a factor of ten. To our satisfac-
tion, conducting the reaction with 10 mmol of 5a under iden-
tical conditions gave an even better yield (92%).
To test the scope of our developed method for the synthesis
of 5-aza-7-deaza-adenines, we prepared a series of substituted
2-aminoimidazoles (5) using the method developed by Van der
Eiken's group22 and then used them as substrates in our
multicomponent reaction with triethyl orthoformate and cyan-
amide. The reaction of diﬀerent 5 proceeded with the formation
of the desired products 6. Various aromatic substituents with
electron-withdrawing and electron-donating groups in diﬀerent
positions were tolerated on 5 in the reaction (Table 2).
In principle, the formation of the aminotriazine ring in the
three-component reaction of 2-aminoimidazoles 5 with triethyl
orthoformate and cyanamide may proceed in four diﬀerent
ways (Scheme 1). Two regioisomeric pairs of isosteres of
adenine (compounds 6 and 7) and isoadenine (compounds 8
and 9) could be theoretically obtained. However, only one
product was isolated from the multicomponent reaction. The
same product was obtained in the independent two-step
synthesis using the general method reported earlier.23 Treat-
ment of 5a with N,N-dimethylformamide dimethylacetal
produced formamidine 11, which was found to exist in DMSO
solution in the equilibrium with its tautomer 110 (Scheme 2).
The formamidine 11 further reacted with cyanamide in the
presence of sodium methoxide aﬀording the triazine ring
formation. This approach excluded formation of 8 and 9, but
the triazine ring closure might happen at any of the two imid-
azole nitrogen atoms resulting in 6 or 7. The unambiguous
structure assignment for the products was done using X-ray
crystallography of 6i (Fig. 1).
It was conrmed that our multicomponent reaction exclu-
sively produced 4-amino-7-arylimidazo[1,2-a][1,3,5]triazines (6).
Their regioisomers 7 are probably less stable due to steric
hindrance between the amino group and the aryl; even if
formed, they immediately rearrange at the reaction conditions
to 6 (Scheme 1). The proposed rearrangement pathway involves
formation of intermediate 10 resembling to the mechanism
suggested for the amino-1,3,5-triazine ring rearrangement in
a similar heterocyclic system.24 The reaction was found to be
highly chemo- and regioselective. Compounds 6 were produced
exclusively for all aminoimidazoles 5 involved in the reaction
and no traces of other isomers were detected.RSC Adv., 2017, 7, 51062–51068 | 51063
Table 1 Optimization of conditions for the synthesis of 8-phenyl-5-aza-7-deaza-adenine (6a)a
Entry Solvent Ratio of 5a : HC(OEt)3 : NCNH2 Temperature (C) Time (min) Isolated yield (%)
1 MeOH 1 : 1.8 : 1.2 150 25 26
2 PhMe 1 : 1.8 : 1.2 150 25 57
3 MeCN 1 : 1.8 : 1.2 150 25 51
4 EtOH 1 : 1.8 : 1.2 150 25 19
5 THF 1 : 1.8 : 1.2 150 25 36
6 AcOEt 1 : 1.8 : 1.2 150 25 61
7 AcOEt 1 : 1.8 : 1.2 150 20 68
8 AcOEt 1 : 1.8 : 1.2 150 15 66
9 AcOEt 1 : 2 : 2 150 20 74
10 AcOEt 1 : 2.5 : 2.5 150 20 83
11 AcOEt 1 : 3 : 3 150 20 56
12 AcOEt 1 : 2.5 : 2.5 140 20 76
a The reaction was performed using a Discover SP CEM microwave synthesizer with 1 mmol of 5a in 2 mL of the solvent.
Table 2 One pot, multicomponent synthesis of 7-aryl substituted 4-aminoimidazo[1,2-a][1,3,5]triazines (6)a
a Microwave-assisted step performed on a 1 mmol scale in EtOAc (2 mL) using a Discover SP CEMmicrowave synthesiser. b Microwave-assisted step
performed on a 10 mmol scale in EtOAc (20 mL) using a Discover SP CEM microwave synthesiser.
51064 | RSC Adv., 2017, 7, 51062–51068 This journal is © The Royal Society of Chemistry 2017
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Scheme 1 Possible annulations of the 1,3,5-triazine ring onto 2-amino-1H-imidazoles.
Scheme 2 Step-wise synthesis of 6a.
Paper RSC AdvancesX-ray crystallography
The molecular structure of 6i is shown in Fig. 1a and comprises
two planar fragments with the r.m.s. deviation of the nine
atoms of the fused ring system being 0.015 A. The maximumFig. 1 (a) Molecular structure of 6i showing atom labelling scheme
and 70% anisotropic displacement parameters, and (b) a view of the
N–H/N hydrogen bonding (blue dashed lines) leading to double-
chains (see ESI Fig. S1‡). The outer four molecules are represented by
only the ispo-C atom of the methoxyphenyl groups for reasons of
clarity.
This journal is © The Royal Society of Chemistry 2017deviation from the least-squares plane is 0.022(1) A for the N3
atom, and the amino-N5 atom lies 0.046(1)A out of the plane in
the opposite direction to N3. A twist in the molecule is indicated
by the dihedral angle of 14.20(3) between the imidazo[1,2-a]
[1,3,5]triazine and phenyl planes. Finally, the methoxy group is
twisted out of the plane of the ring to which it is connected with
the C13–O1–C10–C9 being 172.03(8).
The crystal of 6i comprises double-layers of hydrogen
bonded molecules with a fragment of the array illustrated in
Fig. 1b. Thus, centrosymmetric eight-membered {/HNCN}2
supramolecular synthons are formed between the amine-N–H
and endocyclic nitrogen atoms of triazine residues with the
remaining amine-N–H atom being connected to the second
available triazine-N atom of a diﬀerent molecule. The double-
layers are formed parallel to [0 0 1] and are connected into
a three-dimensional architecture via methyl-C–H/O(methoxy)
and methyl-C–H/N(imidazo) non-conventional hydrogen
bonding. The geometric details for the mentioned intermolec-
ular contacts are given in the ESI Table S1‡ and a view of the
unit cell contents is given in the ESI Fig. S1.‡Conclusions
In summary, we have successfully developed a new, microwave-
assisted, multicomponent reaction for the synthesis of 5-aza-7-
deaza-adenines (6). The catalyst-free reaction was found to
proceed with high selectivity and produce the desired product
in good yields and purity. A rearrangement was suggested to
explain regioselectivity of the ring closure.RSC Adv., 2017, 7, 51062–51068 | 51065
RSC Advances PaperExperimental section
General information
Melting points (uncorrected) were determined on a Stuart™
SMP40 automatic melting point apparatus. 1H and 13C NMR
spectra were recorded on a Bruker Fourier 300 spectrometer
(300 MHz) using DMSO-d6 as a solvent and TMS as an internal
reference. Microwave-assisted reactions were carried out in the
closed vessel focused single mode using a Discover SP micro-
wave synthesizer (CEM, USA) monitoring reaction temperature
by equipped IR sensor. For the method validation, the model
reaction was also carried out using Monowave 450 (Anton Paar,
Austria) and Initiator+ (Biotage, Sweden) reactors.General method for the microwave-assisted synthesis of 5-aza-
7-deaza-adenines (4-aminoimidazo[1,2-a][1,3,5]triazines, 6)
The mixture of a 2-amino-1H-imidazole (5, 1 mmol), cyanamide
(105 mg, 2.5 mmol) and triethyl orthoformate (0.4 mL,
2.5 mmol) in ethyl acetate (2 mL) were irradiated in a 10 mL
seamless pressure vial using microwave system operating at
maximal microwave power up to 150 W at 150 C for 20 min.
Aer cooling, the precipitate was ltered, washed with ethyl
acetate and recrystallised from DMF.
4-Amino-7-phenylimidazo[1,2-a][1,3,5]triazine (6a). Brown
solid, yield 83%, mp 313–315 C (DMF). 1H NMR (300 MHz,
DMSO-d6): d 7.37 (1H, t,
3J ¼ 7.3 Hz, H-40), 7.48 (2H, t, 3J ¼
7.5 Hz, H-30 and H-50), 7.88 (2H, d, 3J ¼ 7.1 Hz, H-20 and H-60),
8.15 (1H, s, H-2), 8.23 (1H, s, H-6), 8.50 (2H, brs, NH2).
13C NMR
(75MHz, DMSO-d6): d 102.1 (C-6), 125.3 (C-20 and C-60), 128.1 (C-
40), 128.8 (C-30 and C-50), 133.1 (C-10), 143.5 (C-7), 149.6 (C-8a),
151.3 (C-4), 155.5 (C-2). Anal. calcd for C11H9N5: C, 62.55; H,
4.29; N, 33.16. Found: C, 62.35; H, 4.37; N, 33.02.
4-Amino-7-(4-uorophenyl)imidazo[1,2-a][1,3,5]triazine (6b).
Brown solid, yield 71%, mp 314–316 C (DMF). 1H NMR (300
MHz, DMSO-d6): d 7.32 (2H, dd,
3J ¼ 9.0 Hz, 3JHF ¼ 9.0 Hz, H-30
and H-50), 7.90 (2H, dd, 3J¼ 8.9 Hz, 4JHF¼ 5.5 Hz, H-20 and H-60),
8.14 (1H, s, H-2), 8.18 (1H, s, H-6), 8.47 (2H, brs, NH2).
13C NMR
(75 MHz, DMSO-d6): d 101.9 (C-6), 115.7 (d,
2JCF ¼ 21.7 Hz, C-30
and C-50), 127.3 (d, 3JCF ¼ 8.3 Hz, C-20 and C-60), 129.6 (d, 4JCF ¼
3.0 Hz, C-10), 142.6 (C-7), 149.6 (C-8a), 151.3 (C-4), 155.5 (C-2),
162.0 (d, 1JCF ¼ 244.8 Hz, C-40). Anal. calcd for C11H8FN5: C,
57.64; H, 3.52; N, 30.55. Found: C, 57.55; H, 3.60; N, 30.28.
4-Amino-7-(2-chlorophenyl)imidazo[1,2-a][1,3,5]triazine (6c).
Yellow solid, yield 73%, mp 312–314 C (DMF). 1H NMR (300
MHz, DMSO-d6): d 7.38 (1H, ddd,
4J ¼ 1.8 Hz, 3J ¼ 7.6 Hz, 3J ¼
7.6 Hz, H-40), 7.47 (1H, ddd, 4J ¼ 1.4 Hz, 3J ¼ 7.6 Hz, 3J ¼ 7.6 Hz,
H-50), 7.57 (1H, dd, 4J ¼ 1.3 Hz, 3J ¼ 7.9 Hz, H-30), 7.95 (1H, s, H-
2), 8.25 (1H, dd, 4J ¼ 1.8 Hz, 3J ¼ 7.9 Hz, H-60), 8.55 (1H, s, H-6),
8.60 (2H, brs, NH2).
13C NMR (75 MHz, DMSO-d6): d 106.3 (C-6),
127.3 (C-60), 129.1 (C-50), 130.3 (C-30), 130.5 (C-40), 130.6 (C-20),
131.2 (C-10), 140.0 (C-7), 148.6 (C-8a), 151.5 (C-4), 155.9 (C-2).
Anal. calcd for C11H8ClN5: C, 53.78; H, 3.28; N, 28.51. Found:
C, 53.59; H, 3.40; N, 28.45.
4-Amino-7-(4-chlorophenyl)imidazo[1,2-a][1,3,5]triazine (6d).
Brown solid, yield 79%, mp 339–340 C (DMF). 1H NMR
(300 MHz, DMSO-d6): d 7.54 (2H, d,
3J ¼ 8.6 Hz, H-30 and H-50),51066 | RSC Adv., 2017, 7, 51062–510687.87 (2H, d, 3J ¼ 8.6 Hz, H-20 and H-60), 8.15 (1H, s, H-2), 8.24
(1H, s, H-6), 8.52 (2H, brs, NH2).
13C NMR (75 MHz, DMSO-d6):
d 102.5 (C-6), 127.0 (C-20 and C-60), 128.9 (C-30 and C-50), 132.0
(C-10), 132.5 (C-40), 142.3 (C-7), 149.7 (C-8a), 151.3 (C-4), 155.7
(C-2). Anal. calcd for C11H8ClN5: C, 53.78; H, 3.28; N, 28.51.
Found: C, 53.63; H, 3.36; N, 28.31.
4-Amino-7-(4-bromophenyl)imidazo[1,2-a][1,3,5]triazine (6e).
Brown solid, yield 79%, mp 341–342 C (DMF). 1H NMR
(300 MHz, DMSO-d6): d 7.68 (2H, d,
3J ¼ 8.6 Hz, H-30 and H-50),
7.81 (2H, d, 3J ¼ 8.6 Hz, H-20 and H-60), 8.14 (1H, s, H-2), 8.25
(1H, s, H-6), 8.51 (2H, brs, NH2).
13C NMR (75 MHz, DMSO-d6):
d 102.6 (C-6), 121.1 (C-40), 127.3 (C-20 and C-60), 131.8 (C-30 and
C-50), 132.3 (C-10), 142.3 (C-7), 149.7 (C-8a), 151.3 (C-4), 155.7
(C-2). Anal. calcd for C11H8BrN5: C, 45.54; H, 2.78; N, 24.14.
Found: C, 45.42; H, 2.88; N, 23.98.
4-Amino-7-(4-iodophenyl)imidazo[1,2-a][1,3,5]triazine (6f).
Brown solid, yield 83%, mp 331–332 C (DMF). 1H NMR
(300 MHz, DMSO-d6): d 7.66 (2H, d,
3J ¼ 8.5 Hz, H-30 and H-50),
7.85 (2H, d, 3J ¼ 8.5 Hz, H-20 and H-60), 8.14 (1H, s, H-2), 8.25
(1H, s, H-6), 8.49 (2H, brs, NH2).
13C NMR (75 MHz, DMSO-d6):
d 94.1 (C-40), 102.5 (C-6), 127.3 (C-20 and C-60), 132.7 (C-10), 137.6
(C-30 and C-50), 142.5 (C-7), 149.6 (C-8a), 151.3 (C-4), 155.6 (C-2).
Anal. calcd for C11H8IN5: C, 39.19; H, 2.39; N, 20.77. Found: C,
39.03; H, 2.44; N, 20.59.
4-Amino-7-(3-nitrophenyl)imidazo[1,2-a][1,3,5]triazine (6g).
Brown solid, yield 86%, mp 296–298 C (DMF). 1H NMR
(300 MHz, DMSO-d6): d 7.79 (1H, t,
3J¼ 8.0 Hz, H-50), 8.18 (1H, s,
H-2), 8.21 (1H, ddd, 4J ¼ 0.9 Hz, 4J ¼ 2.3 Hz, 3J ¼ 8.2 Hz, H-60),
8.27 (1H, ddd, 4J ¼ 1.0 Hz, 4J ¼ 1.6 Hz, 3J ¼ 7.6 Hz, H-40), 8.44
(1H, s, H-6), 8.55 (2H, brs, NH2), 8.64 (1H, dd,
4J ¼ 1.6 Hz, 4J ¼
2.3 Hz, H-20). 13C NMR (75 MHz, DMSO-d6): d 103.7 (C-6), 119.5
(C-20), 122.6 (C-40), 130.6 (C-50), 131.3 (C-60), 134.8 (C-10), 141.1
(C-7), 148.3 (C-30), 149.9 (C-8a), 151.5 (C-4), 156.0 (C-2). Anal.
calcd for C11H8N6O2: C, 51.56; H, 3.15; N, 32.80. Found: C,
51.46; H, 3.27; N, 32.71.
4-Amino-7-(4-methylphenyl)imidazo[1,2-a][1,3,5]triazine (6h).
Brown solid, yield 91%, mp > 380 C (DMF). 1H NMR (300 MHz,
DMSO-d6): d 2.35 (3H, s, Me), 7.28 (2H, d,
3J ¼ 7.9 Hz, H-30 and
H-50), 7.76 (2H, d, 3J ¼ 8.1 Hz, H-20 and H-60), 8.13 (1H, s, H-2),
8.17 (1H, s, H-6), 8.47 (2H, brs, NH2).
13C NMR (75 MHz,
DMSO-d6): d 20.8 (Me), 101.6 (C-6), 125.3 (C-20 and C-60), 129.3
(C-30 and C-50), 130.3 (C-10), 137.5 (C-40), 143.6 (C-7), 149.5 (C-8a),
151.2 (C-4), 155.3 (C-2). Anal. calcd for C12H11N5: C, 63.99; H,
4.92; N, 31.09. Found: C, 63.85; H, 5.06; N, 30.87.
4-Amino-7-(4-methoxyphenyl)imidazo[1,2-a][1,3,5]triazine (6i).
Brown solid, yield 92%, mp > 380 C (DMF). 1H NMR (300 MHz,
DMSO-d6): d 3.81 (3H, s, OMe), 7.05 (2H, d,
3J ¼ 8.9 Hz, H-30 and
H-50), 7.80 (2H, d, 3J ¼ 8.9 Hz, H-20 and H-60), 8.10 (1H, s, H-6),
8.12 (1H, s, H-2), 8.43 (2H, brs, NH2).
13C NMR (75 MHz,
DMSO-d6): d 55.1 (OMe), 100.8 (C-6), 114.2 (C-30 and C-50), 125.6
(C-10), 126.7 (C-20 and C-60), 143.6 (C-7), 149.5 (C-8a), 151.2 (C-4),
155.2 (C-2), 159.3 (C-40). Anal. calcd for C12H11N5O: C, 59.74; H,
4.60; N, 29.03. Found: C, 59.66; H, 4.67; N, 28.91.
4-Amino-7-(3,4-dimethoxyphenyl)imidazo[1,2-a][1,3,5]triazine
(6j). Brown solid, yield 79%, mp 252–254 C (DMF). 1H NMR
(300 MHz, DMSO-d6): d 3.80 (3H, s, OMe), 3.85 (3H, s, OMe), 7.06
(1H, d, 3J ¼ 8.4 Hz, H-50), 7.39–7.45 (2H, m, H-20 and H-60), 8.11This journal is © The Royal Society of Chemistry 2017
Paper RSC Advances(2H, s, H-6 and H-2), 8.40 (2H, brs, NH2).
13C NMR (75 MHz,
DMSO-d6): d 55.3 (OMe), 55.5 (OMe), 101.1 (C-6), 108.9 (C-20),
112.0 (C-50), 117.8 (C-60), 125.9 (C-10), 143.7 (C-7), 148.9 (C-30 and
C-40), (C-8a), 151.1 (C-4), 155.2 (C-2). Anal. calcd for C13H13N5O2:
C, 57.56; H, 4.83; N, 25.82. Found: C, 57.41; H, 4.60; N, 25.59.
4-Amino-7-(4-hydroxy-3-methoxyphenyl)-midazo[1,2-a]
[1,3,5]triazine (6k). Grey solid, yield 85%,mp 273–275 C (DMF).
1H NMR (300MHz, DMSO-d6): d 3.87 (3H, s, OMe), 6.87 (1H, d,
3J
¼ 8.2 Hz, H-50), 7.29 (1H, dd, 4J ¼ 1.9 Hz, 3J ¼ 8.2 Hz, H-60), 7.44
(1H, d, 4J¼ 1.9 Hz, H-20), 8.07 (1H, s, H-6), 8.11 (1H, s, H-2), 8.39
(2H, brs, NH2), 9.21 (1H, s, OH).
13C NMR (75 MHz, DMSO-d6):
d 55.4 (OMe), 100.6 (C-6), 109.4 (C-20), 115.8 (C-50), 118.2 (C-60),
124.5 (C-10), 144.1 (C-7), 146.9 (C-30), 147.7 (C-40), 149.4 (C-8a),
151.1 (C-4), 155.1 (C-2). Anal. calcd for C12H11N5O2: C, 56.03;
H, 4.31; N, 27.22. Found: C, 55.88; H, 4.54; N, 27.06.
4-Amino-7-(biphenyl-4-yl)imidazo[1,2-a][1,3,5]triazine (6l).
Brown solid, yield 90%, mp > 380 C (DMF). 1H NMR (300 MHz,
DMSO-d6): d 7.38 (1H, t,
3J ¼ 7.3 Hz, H-400), 7.49 (2H, t, 3J ¼
7.5 Hz, H-300 and H-500), 7.74 (2H, d, 3J ¼ 7.1 Hz, H-200 and H-600),
7.80 (2H, d, 3J ¼ 8.5 Hz, H-30 and H-50), 7.96 (2H, d, 3J ¼ 8.5 Hz,
H-20 and H-60), 8.15 (1H, s, H-2), 8.27 (1H, s, H-6), 8.49 (2H, brs,
NH2).
13C NMR (75 MHz, DMSO-d6): d 102.2 (C-6), 125.9 (C-20
and C-60), 126.4 (C-200 and C-600), 127.0 (C-30 and C-50), 127.5 (C-
400), 128.9 (C-300 and C-500), 132.2 (C-10), 139.5 (C-100), 139.7 (C-40),
143.1 (C-7), 149.7 (C-8a), 151.3 (C-4), 155.5 (C-2). Anal. calcd for
C17H13N5: C, 71.06; H, 4.56; N, 24.37. Found: C, 70.94; H,
4.62; N, 24.28.
4-Amino-7-(napthalene-2-yl)imidazo[1,2-a][1,3,5]triazine (6m).
Brown solid, yield 83%, mp 317–319 C (DMF). 1H NMR (300
MHz, DMSO-d6):
1H NMR (300 MHz, DMSO-d6): d 7.51–7.58 (2H,
m, H-60 and H-70), 7.91–8.05 (4H, m, H-30, H-40, H-50 and H-80),
8.16 (1H, s, H-2), 8.36 (1H, s, H-6), 8.46 (1H, s, H-10), 8.50 (2H, brs,
NH2).
13C NMR (75 MHz, DMSO-d6): d 102.7, 123.4, 124.1, 126.2,
126.5, 127.6, 128.1, 128.4, 130.5, 132.7, 133.1, 143.4, 149.8, 151.3,
155.6. Anal. calcd for C15H11N5: C, 68.95; H, 4.24; N, 26.80. Found:
C, 68.79; H, 4.41; N, 26.63.Step-wise approach for the synthesis of 4-amino-7-
phenylimidazo[1,2-a][1,3,5]triazine (6a)
N0,N0-Dimethyl-N-[3(5)-phenylimidazolo-5(3)yl formamidine
(11). A mixture of 2-amino-1H-imidazole 5a (320 mg, 2 mmol)
with N,N-dimethylformamide dimethyl acetal (0.4 mL, 3 mmol)
in methanol (5 mL) was heated under reux for 4 h. Upon
completion of the reaction, the solvent was removed under
vacuum and the residue was triturated with diethyl ether. The
precipitate was ltered and recrystallised from toluene to give
pure formamidine 11. Brown solid, yield 58%, mp 133–135 C
(toluene). 1H NMR (300 MHz, DMSO-d6): d 2.94 (3H, s, NMe),
3.07 (3H, s, NMe), 7.10 (2H, t, 3J ¼ 7.3 Hz, H-40), 7.19 (1H, brs,
CH), 7.28 (2H, t, 3J ¼ 7.7 Hz, H-30 and H-50), 7.66 (2H, d, 3J ¼
7.4 Hz, H-20 and H-60), 8.41 (1H, s, CH), 11.23 & 11.64 (1H, brs,
NH). Anal. calcd for C12H14N4: C, 67.27; H, 6.59; N, 26.15.
Found: C, 67.16; H, 6.64; N, 26.08.
4-Amino-7-phenylimidazo[1,2-a][1,3,5]triazine (6a). To the
sodium methoxide solution prepared by dissolving sodium
(60 mg, 2.5 mmol) in methanol (5 mL), formamidine 11This journal is © The Royal Society of Chemistry 2017(215 mg, 1 mmol) and cyanamide (105 mg, 2.5 mmol) were
added. The reaction mixture was heated under reux for 24 h,
cooled and the precipitate was ltered to obtain a compound,
which was identical to 6a prepared using the multicomponent
reaction. Yield 24%.X-Ray crystallographic analysis
The crystals for X-ray diﬀraction study were grown from the very
dilute MeOH solution. Intensity data for 6i were measured at
T ¼ 100(2) K on a SuperNova Dual AtlasS2 diﬀractometer tted
with Mo Ka radiation so that qmax was 33.0. Data reduction,
including absorption correction, was accomplished with Cry-
sAlisPro.25 Of the 29 046 measured reections, 3968 were
unique (Rint ¼ 0.017) and of these, 3510 data satised the I $
2s(I) criterion. The structure was solved by direct-methods26 and
rened (anisotropic displacement parameters, C-bound H
atoms in the riding model approximation, N-bound H atoms
with N–H¼ 0.88 0.01A and a weighting scheme w¼ 1/[s2(Fo2)
+ 0.067P2 + 0.331P] where P ¼ (Fo2 + 2Fc2)/3) on F2.27 Owing to
poor agreement, the (3 3 6) reection was omitted from the
nal cycles of renement. Based on the renement of
170 parameters, the nal values of R and wR (all data) were
0.040 and 0.114, respectively. The molecular structure diagram
was generated with ORTEP for Windows28 and the packing
diagram with DIAMOND.29
Crystal data for 4-amino-7-(4-methoxyphenyl)imidazo[1,2-a]
[1,3,5]triazine (6i). M ¼ 241.26, monoclinic, P21/c, a ¼
6.97780(10), b¼ 12.4862(2), c¼ 12.6501(2)A, b¼ 93.808(2), V¼
1099.72(3) A3, Z ¼ 4, Dx ¼ 1.457 g cm3, F(000) ¼ 504, m ¼
0.100 mm1. CCDC deposition number: 1578001.‡Conﬂicts of interest
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